Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hyperplasia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    157 result(s) found for: Hyperplasia. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2007-002598-30 Sponsor Protocol Number: AEZS-102-036 Start Date*: 2008-02-08
    Sponsor Name:Aeterna Zentaris GmbH
    Full Title: Cetrorelix pamoate in patients with symptomatic BPH: a double-blind placebo-controlled efficacy study
    Medical condition: Benign Prostatic Hyperplasia (PBH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) FR (Completed) BG (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-004811-53 Sponsor Protocol Number: PMX GE IT 304 Start Date*: 2005-04-28
    Sponsor Name:PIERRE FABRE PHARMA
    Full Title: Ex-vivo study regarding the effects of Serenoa r. on the expression of VEGF vascular endothelial growth factor and microvessel density in patients with benign prostatic hypertrophy
    Medical condition: benign prostatic hypertrophy
    Disease: Version SOC Term Classification Code Term Level
    6.1 10004446 PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004764-22 Sponsor Protocol Number: SPR001-203 Start Date*: 2020-10-15
    Sponsor Name:Spruce Biosciences, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia
    Medical condition: Classic Congenital Adrenal Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) SE (Trial now transitioned) DE (Ongoing) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) IT (Trial now transitioned) LT (Trial now transitioned) LV (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004865-17 Sponsor Protocol Number: AEZS-102-041 Start Date*: 2008-08-15
    Sponsor Name:Aeterna Zentaris GmbH
    Full Title: Cetrorelix pamoate (AEZS-102) in patients with symptomatic BPH: an open-labeled safety and efficacy assessment study
    Medical condition: Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004381-19 Sponsor Protocol Number: NBI-74788-CAH2006 Start Date*: 2021-06-07
    Sponsor Name:Neurocrine Biosciences, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by O...
    Medical condition: Classic Congenital Adrenal Hyperplasia (CAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GR (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002796-32 Sponsor Protocol Number: BAY 38-9456 / 11863 Start Date*: 2005-10-17
    Sponsor Name:Bayer Healthcare AG
    Full Title: A randomized, double-blind, placebo-controlled, multi-center, parallel group study to assess the efficacy of vardenafil in the treatment of symtomatic Benign Prostatic Hyperplasia
    Medical condition: Benigne Prostatic Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    8.0 10004446 LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003414-34 Sponsor Protocol Number: D-20762-Z033 Start Date*: 2007-11-12
    Sponsor Name:Aeterna Zentaris GmbH
    Full Title: Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1year placebo-controlled efficacy study and long-term safety assessment
    Medical condition: Benign Prostatic Hyperplasia (PBH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-005252-32 Sponsor Protocol Number: 027SC06018 Start Date*: 2006-12-14
    Sponsor Name:ANGELINI
    Full Title: A PILOT STUDY OF PRULIFLOXACIN VS. LEVOFLOXACIN IN PREVENTION OF POST-OPERATIVE URINARY BACTERIAL INFECTIONS IN PATIENTS UNDERGOING TURP
    Medical condition: ANTIBIOTIC PROPHYLAXIS FOR TRANSURETHRAL PROSTATIC RESECTION
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001212-20 Sponsor Protocol Number: 905-CL-057 Start Date*: 2009-07-16
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: An open-label, long term multi-center study to assess the safety and efficacy of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg, in male ...
    Medical condition: Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) AT (Completed) IT (Completed) DE (Completed) FR (Completed) HU (Completed) SK (Completed) BE (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-004878-34 Sponsor Protocol Number: ATR-101-202 Start Date*: 2018-09-18
    Sponsor Name:Millendo Therapeutics, Inc.
    Full Title: A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia
    Medical condition: Classic Congenital Adrenal Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000154-76 Sponsor Protocol Number: BXL628 02 14 Start Date*: 2005-03-16
    Sponsor Name:BIOXELL SPA
    Full Title: A randomized, double blind, double dummy, placebo controlled, parallel group study to determine the effect of BXL628 in monotherapy 75 mcg and 150 mcg and in combination 150 mcg with tamsulosi...
    Medical condition: Benign prostatic hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    6.1 10004446 PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005822-23 Sponsor Protocol Number: REK231814 Start Date*: 2012-10-16
    Sponsor Name:Haukeland University Hospital
    Full Title: CONTINUOUS SUBCUTANEOUS HYDROCORTISONE INFUSION IN CONGENITAL ADRENAL HYPERPLASIA
    Medical condition: Congenital adrenal hyperplasia (CAH)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002841-21 Sponsor Protocol Number: H6D-MC-LVHJ(a) Start Date*: 2008-10-28
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of B...
    Medical condition: Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005793-31 Sponsor Protocol Number: 304001 Start Date*: 2008-04-16
    Sponsor Name:NV Organon
    Full Title: A phase II, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Org 3236 tablets in men with Lower Urinary Tract Symptoms (LUTS) suggestive of Benign Prostat...
    Medical condition: Benign prostatic hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) GB (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-004321-15 Sponsor Protocol Number: H6D-MC-LVHK(b) Start Date*: 2007-12-14
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Urodynamic Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign P...
    Medical condition: Effects on urodynamic parameters in men with benign prostatic hyperplasia (also referred to as BPH-LUTS [lower urinary tract symptoms]) with and without urodynamic evidence of bladder outlet obstru...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000915-53 Sponsor Protocol Number: DEXAPAE Start Date*: 2020-10-08
    Sponsor Name:Department of Radiology, Rigshospitalet, Denmark
    Full Title: Randomized double-blind placebo-controlled trial on the efficiency of a single dose dexamethasone in reducing the postembolization syndrome in men undergoing prostatic artery embolization for benig...
    Medical condition: Benign prostatic hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004873-17 Sponsor Protocol Number: NBI-74788-CAH3003 Start Date*: 2020-10-15
    Sponsor Name:Neurocrine Biosciences, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-...
    Medical condition: Classic Congenital Adrenal Hyperplasia (CAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) NL (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-001073-94 Sponsor Protocol Number: TH CR-202 Start Date*: 2005-12-27
    Sponsor Name:Threshold Pharmaceuticals Inc
    Full Title: A Randomised Phase 3, Double Blind, Placebo-Controlled Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
    Medical condition: Benign Prostatic Hyperplasia
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed) IT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002395-40 Sponsor Protocol Number: AGO/2013/007 Start Date*: 2014-03-24
    Sponsor Name:Ghent University Hospital
    Full Title: Prospective intervention trial with adjuvant metformin in girls and boys with classic CAH (METFOR CAH).
    Medical condition: congenital adrenal hyperplasia (CAH)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000848-83 Sponsor Protocol Number: CSO181 Start Date*: 2005-07-06
    Sponsor Name:GlaxoSmithKline Consumer Healthcare GmbH & Co KG, 77815 Bühl
    Full Title: Teilverblindete, randomisierte, Placebo-kontrollierte, multizentrische Studie zur Wirksamkeit von Dickextrakt aus Kürbissamen (Kürbissamen-Extrakt) und Kürbissamen bei Patienten mit benigner Prosta...
    Medical condition: benign prostatic hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    8.0 10004446 LLH
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 19:12:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA